Mouse Monoclonal Antibody (CAL2) Against All CALRETTICULIN (CALR) Mutations

Product Information

**Catalog No.:**
- DIA-CAL-250 (250μl, lyophilized powder)
- DIA-CAL-100 (100μl, liquid)

**Clone:**
CAL2

**Isotype:**
Mouse IgG2a

**Immunogen:**
C-neoterminal of mutated CALR.

**Specificity:**
Human CALR protein expressed by all types of Exon 9 CALR mutations (deletion/insertion in 19p 13.3-13.2 of)

**Application:**
Immunohistochemistry (IHC) for formalin-fixed paraffin-embedded (FFPE) tissue with or without EDTA-decalcification. Other fixatives (e.g. Bouin) not tested.

**Physical state:**
Lyophilized powder

**Reagent provided:**
Antibody purified from culture supernatant in PBS with 2% BSA, 0.05% NaN3, pH 7.4.

**Storage and stability:**
Store reconstituted liquid for at least one year at -20°C. Stable for at least one year at -20°C. Avoid repeated freeze/thaw cycles.

**Instructions for use:**
Reconstitute DIA-CAL-250 with 250 μl sterile distilled water followed by gentle shaking for 10 minutes. Pre-treat the deparaffinized sections with the heat induced epitope retrieval (HER) technique; recommended is to heat the sections in citrate buffer pH 6.0 in a pressure cooker for 10 minutes. Other HIER techniques are also applicable. The sections treated by HIER can be processed by all standard IHC protocols. The CAL2 antibody IHC is suited for using automated platforms.

**Dilution:**
Apply CAL2 at a dilution of 1:20-1:40 for IHC.

**General recommendation:**
Validation of antibody performance/protocol is the responsibility of the end user. Positive/negative controls should be run simultaneously with tissue specimen.

**Practical implementation:**
CAL2 labels the megakaryocytes in myeloproliferative neoplasms (essential thrombocythaemia (ET) and primary myelofibrosis (PMF)) with CALR mutation and enables to distinguish ET and PMF with CALR mutation from polycythemia vera (PV), from CALR mutation negative ET and PMF and from reactive bone marrow.

**Staining pattern:**
Cytoplasmic staining of megakaryocytes harboring CALR mutation. The CAL2 IHC assay indicates absence of CALR mutation when all megakaryocytes remain unlabeled.

**Positive control:**
Megakaryocytes from CALR mutated PMNs

**Negative control:**
Megakaryocytes of reactive bone marrow specimens or JAK2 mutated PV

**Safety notes:**
The reconstituted liquid contains 0.05% sodium azide as a preservative. Avoid skin and eye contact, inhalation and ingestion.

**References:**

For research use only. Not for diagnostic or therapeutic use.